Mitochondrial-derived peptides: the signals your engines stop sending

Your mitochondria have a second job. The first one everybody knows — they’re the tiny engines inside almost every cell, the things that turn your food into usable energy. The second job is newer, and stranger. They talk.

Your engines send out short chemical messages that slip into the bloodstream and tell the rest of the body how hard they’re working and what to do about it. A whole family of those messages turned up in the last decade. Nobody knew it was there. And the amount of it circulating in you fades as the years stack up — which is exactly why a corner of the longevity world can’t stop talking about it. If your cells send instructions to run younger, and those instructions dry up with age, the question writes itself. What happens if you put them back?

What a whole family of these signals could do for you

Start with the thing every member of this family points at: fuel. These are metabolic signals. In the lab, the best-studied one makes muscle better at pulling sugar out of the blood and burning it — the same thing that goes right when you’re lean and fit, and the same thing that drifts wrong through your forties. Give it to animals and their metabolism swings back toward the younger setting: less fat stored, sugar handled like a leaner body handles it, more staying power under load.

Put the family’s promise in one line. A set of signals, made by your own cells, that could nudge an ageing metabolism back toward how it ran at thirty. That is about as close to the whole longevity wish list as a class of molecules gets. It’s a genuinely exciting idea — and it’s early, which is the honest other half of the sentence.

The member carrying almost all of that promise is MOTs-c, and it earns its own read: what MOTs-c could actually do for you. Here we’re one level up. What is this family, and why does a category nobody had a name for ten years ago matter?

Why a genuinely new kind of signal is worth the excitement

For decades the textbook was blunt about your mitochondria’s own DNA. That DNA is a tiny loop, separate from the big genome coiled up in the cell’s nucleus, and the loop was supposed to do one narrow job: build a few parts for the energy machinery. That was the whole story.

The story was wrong. Buried in that little loop are short stretches of code that get read and translated into small peptides — and those peptides leave the mitochondria and act like hormones. Biologists gave the family a name: mitochondrial-derived peptides, or MDPs. The prototype, and the one you’ll actually meet on a research-chemical site, is MOTs-c — a 16-amino-acid signal Lee and colleagues at USC pinned down in 2015. Behind it sit the rest of the family: the humanin group and the SHLP1–6 series. Same basic idea, far less studied.

That’s what makes this more interesting than the average compound. A message from the engine room, written in a language your cells already read. It isn’t a molecule lifted from somewhere else in biology and repurposed. It’s a signal your own body runs on, only pinned down in the last decade, and the idea more or less writes itself: hand it back as the level drops, in the exact form your cells already know how to use.

How much of this is actually proven

Now the clarity. Hope only counts if it survives it. Almost all of the class’s evidence rests on one member. MOTs-c has a clean animal mechanism, a stack of human association data, and a single small human trial — and even that trial moved the signal with heat, not with an injection. In 2025 Elhusseiny and colleagues put nineteen active men through a stretch of calf immobilisation and raised their circulating MOTs-c with repeated heat exposure. It’s a real human study. The thing that moved the peptide was a sauna-style stress, not a needle. The full accounting is in the MOTs-c deep-dive.

The rest of the family is thinner still. Humanin and the SHLPs are real peptides doing real things in a dish, but no controlled human trial has handed any of them to a person and measured what changes. The 2022 review that maps the class is honest about that gap — most of what we know about these peptides in people is measured, not tested. Circulating levels run lower in older people and lower again in people carrying metabolic trouble. That tells you the family is wrapped up in the things you care about. It doesn’t tell you that injecting a member fixes them.

So the honest position is the same one. The mechanism is real and unusually clean for this corner of the market. The human proof isn’t finished, and for most of the family it has barely started. The trial that would settle it — give middle-aged adults one of these peptides, measure their metabolism and strength against placebo — simply hasn’t been run.

Which member the FDA is actually looking at

Only one peptide in this family is anywhere near the US regulatory system. Just the one. MOTs-c is on the FDA Pharmacy Compounding Advisory Committee’s July 23, 2026 docket per Federal Register notice 2026-07361, listed for evaluation under obesity and osteoporosis — not longevity, not the exercise-mimic pitch the market runs on. The committee is being asked a narrow question: whether US-licensed pharmacies should be allowed to compound MOTs-c for those specific medical uses. What a review like that can and can’t decide is its own subject, laid out in what a PCAC review actually is.

The rest of the family sits outside all of it. Humanin and the SHLPs aren’t on the July 2026 docket or the second meeting scheduled before the end of February 2027. MOTs-c is the only mitochondrial-derived peptide in the current review window at all.

Anti-doping is a quick note. MOTs-c isn’t named on the current WADA prohibited list, but its whole metabolic-and-endurance profile is exactly the activity class WADA watches — so if you compete, check the code on the day rather than trusting this line.

Where that leaves the class

The mitochondrial-derived peptides are a real and unusually clean piece of biology. Short signals encoded inside your own engines, acting like metabolic hormones — a category that didn’t exist in a textbook ten years ago. One member has a coherent story and the early human hints to go with it; the rest are earlier still. This is the kind of thing you build a hypothesis around, not the kind you dose yourself on off a rodent study and an overseas vial.

The version worth being excited about isn’t that vial. It looks like a physician prescribing against a real indication, a US-licensed pharmacy compounding it, and an assay on every batch before it ships. Building precisely that is the point of Wolverine Health — the aboveboard version of what people are already sourcing the risky way. It can’t open until the regulation catches up, and that’s the plain reason it hasn’t yet. July 23 is the first time a US regulator looks hard at any peptide in this family. Leave your email and we’ll walk you through what the decision means for buying one legally, the week it comes down.